logo

Global Recombinant DNA (rDNA) Technology Market Size (2024 - 2029)

The recombinant DNA technology market is experiencing growth driven by its expanding application in developing therapeutics and diagnostics, particularly highlighted during the COVID-19 pandemic. This technology is pivotal in creating vaccines and pharmaceuticals, enhancing treatment strategies through diagnostics and monitoring devices, and offering innovation opportunities in medical genetics and biomedicine. The market's expansion is further supported by product launches, such as genetically modified organisms for various applications. Despite these growth drivers, the market faces potential constraints due to regulatory, scientific, and ethical challenges associated with recombinant DNA technology and gene therapy.

Home Market Analysis Healthcare Research Biotechnology Research Biopharma Research Recombinant Products Research Recombinant DNA Technology Market Market Size

Market Size of Global Recombinant DNA (rDNA) Technology Industry

CAGR
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.80 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Recombinant DNA (rDNA) Technology Market Analysis

The recombinant DNA (rDNA) technology market is projected to register a CAGR of 6.8% during the forecast period (2022-2027).

The COVID-19 pandemic had a positive impact on the market studied, as it increased the demand for recombinant DNA technology in the development of therapeutics and diagnostics. For instance, in November 2020, a research paper published in the United States National Library of Medicine titled "Recombinant vaccines for COVID-19" stated that the recombinant COVID-19 vaccine can overcome limitations and the safety concerns associated with other vaccines. Moreover, many COVID-19 vaccines have been manufactured by several companies based on recombinant DNA technology. Likewise, as per the article titled "A review on Promising vaccine development progress for COVID-19 disease" published in November 2020 in the National Library of Medicine, the COVID-19 vaccines are being developed using cutting-edge recombinant technology, in addition, to live vectored and inactivated viruses. Hence, such factors are ultimately boosting the demand for recombinant DNA technology in developing vaccines for COVID-19, thereby boosting the market growth over the coming years.

Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. Moreover, the treatment strategies are improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Additionally, many other industries are benefiting from the research conducted on genetically modified organisms (GMOs), such as microorganisms that are considered clean fuel producers and biodegraders. Genetically modified vaccines are developed to cure various diseases in humans and plants. Recombinant DNA technology has created several potential innovation opportunities for developing a wide range of therapeutic products with immediate effect in medical genetics and biomedicine by modifying microorganisms, animals, and plants to yield medically useful substances.

Product launches are another factor accelerating the growth of the market. For instance, in September 2021, a Tokyo-based start-up called Sanatech Seed Co. teamed up with scientists at the University of Tsukuba to develop a new variety of tomatoes with the help of CRISPR/Cas9 gene-editing technology. The first products offered were seeds, delivered free of charge to around 4,200 people. The company has started selling genetically modified tomatoes. Such launches will increase the growth of the market in the coming future.

Thus, the increasing demand and application of RDT in various sectors are driving the growth of the market studied. However, regulatory, scientific, and ethical challenges associated with rDNA technology and gene therapy may restrain the growth of the market.

Recombinant DNA (rDNA) Technology Industry Segmentation

As per the scope of the report, recombinant DNA technology is a process in which the creation and manipulation of DNA sequences are done in a specific order, resulting in the production of genetically modified organisms and products. Recombinant DNA is primarily used in conventional and non-conventional applications, such as medicinal, agricultural, and industrial. In medicine, recombinant DNA has been used for the mass production of insulin, Follistim, human growth hormones, monoclonal antibodies, human albumin, vaccines, and other drugs. The recombinant DNA (rDNA) technology market is segmented by product (medical (therapeutic agent, human protein, and vaccine), non-medical (biotech crops, specialty chemicals, and other non-medical products), component (expression system, and cloning vector), application (food and agriculture, health and disease, environment, and other applications), end user (biotechnology and pharmaceutical companies, academic and government research institutes, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above-mentioned segments.

By Product
Medical
Therapeutic Agent
Human Protein
Vaccine
Non-medical
Biotech Crops
Specialty Chemicals
Other Non-medical Products
By Component
Expression System
Cloning Vector
By Application
Food and Agriculture
Health and Disease
Environment
Other Applications
By End User
Biotechnology and Pharmaceutical Companies
Academic and Government Research Institutes
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Recombinant DNA (rDNA) Technology Market Size Summary

The recombinant DNA technology market is experiencing significant growth, driven by its critical role in developing new vaccines and pharmaceuticals, as well as its applications in diagnostics and therapeutic strategies. The COVID-19 pandemic has notably accelerated this growth, as the technology was pivotal in the rapid development of vaccines, overcoming limitations and safety concerns associated with traditional vaccines. This surge in demand is further supported by advancements in genetically modified organisms, which are being utilized across various industries, including agriculture and biomedicine, to produce medically useful substances and improve crop yields. The market is also witnessing increased activity in product launches, such as the development of genetically modified tomatoes using CRISPR/Cas9 technology, which is expected to contribute to future market expansion.

The market's growth is further bolstered by regulatory approvals and initiatives in regions like North America, where the presence of biopharmaceutical companies and supportive regulatory frameworks enhance market dynamics. The United States, in particular, holds a significant market share due to its robust biopharmaceutical manufacturing sector. Additionally, research studies and clinical trials, such as those focusing on poultry vaccines and Alzheimer's disease prevention, are propelling the market forward. The competitive landscape is marked by the presence of major players like GenScript, New England Biolabs, GlaxoSmithKline, Pfizer, and Sanofi, who are actively contributing to market advancements through new product launches and strategic collaborations. Despite the promising growth prospects, the market faces challenges related to regulatory, scientific, and ethical concerns, which may impact its trajectory.

Explore More

Global Recombinant DNA (rDNA) Technology Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Technological Advancements in Genomics

      2. 1.2.2 Expansion of Biopharmaceutical Industry

      3. 1.2.3 Increasing Demand and Applications of Recombinant/ Genetically Modified Products

    3. 1.3 Market Restraints

      1. 1.3.1 Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Product

      1. 2.1.1 Medical

        1. 2.1.1.1 Therapeutic Agent

        2. 2.1.1.2 Human Protein

        3. 2.1.1.3 Vaccine

      2. 2.1.2 Non-medical

        1. 2.1.2.1 Biotech Crops

        2. 2.1.2.2 Specialty Chemicals

        3. 2.1.2.3 Other Non-medical Products

    2. 2.2 By Component

      1. 2.2.1 Expression System

      2. 2.2.2 Cloning Vector

    3. 2.3 By Application

      1. 2.3.1 Food and Agriculture

      2. 2.3.2 Health and Disease

      3. 2.3.3 Environment

      4. 2.3.4 Other Applications

    4. 2.4 By End User

      1. 2.4.1 Biotechnology and Pharmaceutical Companies

      2. 2.4.2 Academic and Government Research Institutes

      3. 2.4.3 Other End Users

    5. 2.5 Geography

      1. 2.5.1 North America

        1. 2.5.1.1 United States

        2. 2.5.1.2 Canada

        3. 2.5.1.3 Mexico

      2. 2.5.2 Europe

        1. 2.5.2.1 Germany

        2. 2.5.2.2 United Kingdom

        3. 2.5.2.3 France

        4. 2.5.2.4 Italy

        5. 2.5.2.5 Spain

        6. 2.5.2.6 Rest of Europe

      3. 2.5.3 Asia-Pacific

        1. 2.5.3.1 China

        2. 2.5.3.2 Japan

        3. 2.5.3.3 India

        4. 2.5.3.4 Australia

        5. 2.5.3.5 South korea

        6. 2.5.3.6 Rest of Asia-Pacific

      4. 2.5.4 Middle East and Africa

        1. 2.5.4.1 GCC

        2. 2.5.4.2 South Africa

        3. 2.5.4.3 Rest of Middle East and Africa

      5. 2.5.5 South America

        1. 2.5.5.1 Brazil

        2. 2.5.5.2 Argentina

        3. 2.5.5.3 Rest of South America

Global Recombinant DNA (rDNA) Technology Market Size FAQs

The Global Recombinant DNA (rDNA) Technology Market is projected to register a CAGR of 6.80% during the forecast period (2024-2029)

New England Biolabs, GlaxoSmithKline plc, Pfizer, Sanofi and GenScript are the major companies operating in the Global Recombinant DNA (rDNA) Technology Market.

Recombinant DNA Technology Market Report Snapshots

Recombinant DNA Technology Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)